nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—SLC22A6—Hydrochlorothiazide—nephrolithiasis	0.311	1	CbGbCtD
Captopril—Persistent dry cough—Hydrochlorothiazide—nephrolithiasis	0.0645	0.246	CcSEcCtD
Captopril—REN—renal vein—nephrolithiasis	0.0535	0.186	CbGeAlD
Captopril—REN—loop of Henle—nephrolithiasis	0.0497	0.173	CbGeAlD
Captopril—REN—renal artery—nephrolithiasis	0.0359	0.125	CbGeAlD
Captopril—REN—collecting duct of renal tubule—nephrolithiasis	0.0282	0.0984	CbGeAlD
Captopril—Serum potassium increased—Hydrochlorothiazide—nephrolithiasis	0.0213	0.0811	CcSEcCtD
Captopril—Airway obstruction NOS—Hydrochlorothiazide—nephrolithiasis	0.0188	0.0717	CcSEcCtD
Captopril—SLC22A6—Organic anion transport—SLC22A12—nephrolithiasis	0.0175	0.125	CbGpPWpGaD
Captopril—ACE—renal artery—nephrolithiasis	0.0153	0.0533	CbGeAlD
Captopril—Obstructive airways disorder—Hydrochlorothiazide—nephrolithiasis	0.0136	0.0518	CcSEcCtD
Captopril—REN—nephron—nephrolithiasis	0.0126	0.0438	CbGeAlD
Captopril—MMP2—nephron—nephrolithiasis	0.0116	0.0402	CbGeAlD
Captopril—Blood potassium increased—Hydrochlorothiazide—nephrolithiasis	0.0102	0.039	CcSEcCtD
Captopril—REN—urine—nephrolithiasis	0.0101	0.0351	CbGeAlD
Captopril—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.00813	0.0583	CbGpPWpGaD
Captopril—ALB—Scavenging of heme from plasma—AMBP—nephrolithiasis	0.00804	0.0576	CbGpPWpGaD
Captopril—Gastric irritation—Hydrochlorothiazide—nephrolithiasis	0.00796	0.0303	CcSEcCtD
Captopril—F2—urine—nephrolithiasis	0.00703	0.0245	CbGeAlD
Captopril—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.00587	0.0224	CcSEcCtD
Captopril—ACE—nephron—nephrolithiasis	0.00536	0.0187	CbGeAlD
Captopril—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.005	0.0358	CbGpPWpGaD
Captopril—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.00462	0.0176	CcSEcCtD
Captopril—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.00457	0.0174	CcSEcCtD
Captopril—ACE—urine—nephrolithiasis	0.0043	0.015	CbGeAlD
Captopril—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.00403	0.0154	CcSEcCtD
Captopril—MMP9—Osteopontin Signaling—SPP1—nephrolithiasis	0.00379	0.0272	CbGpPWpGaD
Captopril—LTA4H—nephron tubule—nephrolithiasis	0.00352	0.0122	CbGeAlD
Captopril—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.00351	0.0134	CcSEcCtD
Captopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.00322	0.0231	CbGpPWpGaD
Captopril—ALB—Binding and Uptake of Ligands by Scavenger Receptors—AMBP—nephrolithiasis	0.00321	0.023	CbGpPWpGaD
Captopril—LTA4H—renal system—nephrolithiasis	0.0032	0.0111	CbGeAlD
Captopril—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.00316	0.0121	CcSEcCtD
Captopril—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.00314	0.0225	CbGpPWpGaD
Captopril—LTA4H—kidney—nephrolithiasis	0.00309	0.0108	CbGeAlD
Captopril—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00303	0.0116	CcSEcCtD
Captopril—LTA4H—cortex of kidney—nephrolithiasis	0.00301	0.0105	CbGeAlD
Captopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00294	0.0211	CbGpPWpGaD
Captopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00294	0.0211	CbGpPWpGaD
Captopril—MMP2—Osteopontin-mediated events—SPP1—nephrolithiasis	0.00289	0.0207	CbGpPWpGaD
Captopril—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00279	0.0106	CcSEcCtD
Captopril—REN—nephron tubule—nephrolithiasis	0.00271	0.00945	CbGeAlD
Captopril—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00258	0.00982	CcSEcCtD
Captopril—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00973	CcSEcCtD
Captopril—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00973	CcSEcCtD
Captopril—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00248	0.00946	CcSEcCtD
Captopril—REN—renal system—nephrolithiasis	0.00247	0.00859	CbGeAlD
Captopril—REN—kidney—nephrolithiasis	0.00239	0.00831	CbGeAlD
Captopril—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00905	CcSEcCtD
Captopril—REN—cortex of kidney—nephrolithiasis	0.00232	0.00809	CbGeAlD
Captopril—MMP2—renal system—nephrolithiasis	0.00227	0.0079	CbGeAlD
Captopril—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00225	0.00857	CcSEcCtD
Captopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00223	0.016	CbGpPWpGaD
Captopril—MMP2—kidney—nephrolithiasis	0.00219	0.00764	CbGeAlD
Captopril—MMP2—cortex of kidney—nephrolithiasis	0.00214	0.00744	CbGeAlD
Captopril—MMP9—Endochondral Ossification—PTH—nephrolithiasis	0.00211	0.0151	CbGpPWpGaD
Captopril—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00211	0.00803	CcSEcCtD
Captopril—CYP2D6—urine—nephrolithiasis	0.0021	0.00732	CbGeAlD
Captopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.00207	0.0149	CbGpPWpGaD
Captopril—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00205	0.0078	CcSEcCtD
Captopril—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00198	0.00753	CcSEcCtD
Captopril—MMP9—renal system—nephrolithiasis	0.00197	0.00687	CbGeAlD
Captopril—SLC22A6—nephron tubule—nephrolithiasis	0.00194	0.00675	CbGeAlD
Captopril—MMP9—kidney—nephrolithiasis	0.00191	0.00664	CbGeAlD
Captopril—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.0019	0.00724	CcSEcCtD
Captopril—MMP9—Osteopontin-mediated events—SPP1—nephrolithiasis	0.00189	0.0136	CbGpPWpGaD
Captopril—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00189	0.00719	CcSEcCtD
Captopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00185	0.0132	CbGpPWpGaD
Captopril—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00181	0.0069	CcSEcCtD
Captopril—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00179	0.00682	CcSEcCtD
Captopril—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00178	0.0068	CcSEcCtD
Captopril—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00674	CcSEcCtD
Captopril—F2—Cell surface interactions at the vascular wall—SLC7A9—nephrolithiasis	0.00174	0.0125	CbGpPWpGaD
Captopril—F2—renal system—nephrolithiasis	0.00172	0.00599	CbGeAlD
Captopril—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00171	0.00652	CcSEcCtD
Captopril—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.0017	0.00647	CcSEcCtD
Captopril—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00168	0.00641	CcSEcCtD
Captopril—F2—kidney—nephrolithiasis	0.00166	0.00579	CbGeAlD
Captopril—SLC22A6—cortex of kidney—nephrolithiasis	0.00166	0.00578	CbGeAlD
Captopril—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00163	0.0117	CbGpPWpGaD
Captopril—SLC15A1—nephron tubule—nephrolithiasis	0.00161	0.00562	CbGeAlD
Captopril—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00161	0.00614	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—AQP1—nephrolithiasis	0.00156	0.0112	CbGpPWpGaD
Captopril—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00155	0.00592	CcSEcCtD
Captopril—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00155	0.00591	CcSEcCtD
Captopril—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00154	0.00586	CcSEcCtD
Captopril—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00151	0.0108	CbGpPWpGaD
Captopril—SLC15A1—renal system—nephrolithiasis	0.00147	0.00511	CbGeAlD
Captopril—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00147	0.00559	CcSEcCtD
Captopril—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00144	0.00548	CcSEcCtD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00144	0.0103	CbGpPWpGaD
Captopril—SLC15A1—kidney—nephrolithiasis	0.00142	0.00494	CbGeAlD
Captopril—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00137	0.00522	CcSEcCtD
Captopril—LTA4H—Metabolism—GRHPR—nephrolithiasis	0.00136	0.00973	CbGpPWpGaD
Captopril—Tension—Hydrochlorothiazide—nephrolithiasis	0.00132	0.00505	CcSEcCtD
Captopril—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00132	0.00504	CcSEcCtD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00132	0.00943	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00132	0.00943	CbGpPWpGaD
Captopril—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00131	0.00499	CcSEcCtD
Captopril—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00127	0.00485	CcSEcCtD
Captopril—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00477	CcSEcCtD
Captopril—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00475	CcSEcCtD
Captopril—MMP2—Degradation of the extracellular matrix—SPP1—nephrolithiasis	0.00124	0.00889	CbGpPWpGaD
Captopril—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00123	0.0047	CcSEcCtD
Captopril—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00122	0.00464	CcSEcCtD
Captopril—MMP9—FGF signaling pathway—SPP1—nephrolithiasis	0.00121	0.0087	CbGpPWpGaD
Captopril—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00121	0.00461	CcSEcCtD
Captopril—LTA4H—Metabolism—AGXT—nephrolithiasis	0.00121	0.00867	CbGpPWpGaD
Captopril—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00119	0.00454	CcSEcCtD
Captopril—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00119	0.00452	CcSEcCtD
Captopril—Cough—Hydrochlorothiazide—nephrolithiasis	0.00118	0.00449	CcSEcCtD
Captopril—ACE—nephron tubule—nephrolithiasis	0.00116	0.00403	CbGeAlD
Captopril—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00115	0.00438	CcSEcCtD
Captopril—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00115	0.00438	CcSEcCtD
Captopril—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00115	0.00438	CcSEcCtD
Captopril—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00114	0.00433	CcSEcCtD
Captopril—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00428	CcSEcCtD
Captopril—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00111	0.00423	CcSEcCtD
Captopril—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.0011	0.0042	CcSEcCtD
Captopril—Shock—Hydrochlorothiazide—nephrolithiasis	0.00108	0.00413	CcSEcCtD
Captopril—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00108	0.00411	CcSEcCtD
Captopril—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00108	0.0041	CcSEcCtD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00107	0.00765	CbGpPWpGaD
Captopril—MMP9—Endochondral Ossification—SPP1—nephrolithiasis	0.00106	0.0076	CbGpPWpGaD
Captopril—ACE—renal system—nephrolithiasis	0.00105	0.00366	CbGeAlD
Captopril—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00105	0.004	CcSEcCtD
Captopril—F2—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00105	0.00749	CbGpPWpGaD
Captopril—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00103	0.00392	CcSEcCtD
Captopril—LTA4H—Metabolism—APRT—nephrolithiasis	0.00103	0.00737	CbGpPWpGaD
Captopril—LTA4H—Metabolism—SLC26A1—nephrolithiasis	0.00103	0.00737	CbGpPWpGaD
Captopril—ACE—kidney—nephrolithiasis	0.00102	0.00354	CbGeAlD
Captopril—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.001	0.00382	CcSEcCtD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000997	0.00714	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000997	0.00714	CbGpPWpGaD
Captopril—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000996	0.0038	CcSEcCtD
Captopril—ACE—cortex of kidney—nephrolithiasis	0.00099	0.00345	CbGeAlD
Captopril—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000989	0.00377	CcSEcCtD
Captopril—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000982	0.00374	CcSEcCtD
Captopril—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000979	0.00373	CcSEcCtD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000976	0.007	CbGpPWpGaD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000976	0.007	CbGpPWpGaD
Captopril—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00097	0.00369	CcSEcCtD
Captopril—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000958	0.00365	CcSEcCtD
Captopril—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00095	0.00362	CcSEcCtD
Captopril—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000942	0.00359	CcSEcCtD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000935	0.0067	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000927	0.00664	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000927	0.00664	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000915	0.00656	CbGpPWpGaD
Captopril—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000908	0.00346	CcSEcCtD
Captopril—F2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000906	0.0065	CbGpPWpGaD
Captopril—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000901	0.00343	CcSEcCtD
Captopril—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000871	0.00332	CcSEcCtD
Captopril—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.000871	0.00332	CcSEcCtD
Captopril—MMP2—Direct p53 effectors—SPP1—nephrolithiasis	0.000864	0.00619	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000826	0.00592	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00082	0.00588	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00082	0.00588	CbGpPWpGaD
Captopril—MMP9—Degradation of the extracellular matrix—SPP1—nephrolithiasis	0.000814	0.00583	CbGpPWpGaD
Captopril—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00079	0.00301	CcSEcCtD
Captopril—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000779	0.00297	CcSEcCtD
Captopril—F2—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000756	0.00542	CbGpPWpGaD
Captopril—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000754	0.00287	CcSEcCtD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00074	0.0053	CbGpPWpGaD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00074	0.0053	CbGpPWpGaD
Captopril—LTA4H—Metabolism—AQP1—nephrolithiasis	0.000733	0.00525	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000731	0.00524	CbGpPWpGaD
Captopril—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000729	0.00278	CcSEcCtD
Captopril—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.0007	0.00267	CcSEcCtD
Captopril—Rash—Hydrochlorothiazide—nephrolithiasis	0.000695	0.00265	CcSEcCtD
Captopril—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000694	0.00264	CcSEcCtD
Captopril—Headache—Hydrochlorothiazide—nephrolithiasis	0.00069	0.00263	CcSEcCtD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000688	0.00493	CbGpPWpGaD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000688	0.00493	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000676	0.00484	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000668	0.00479	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000668	0.00479	CbGpPWpGaD
Captopril—LTA4H—Metabolism—CHRM3—nephrolithiasis	0.000663	0.00475	CbGpPWpGaD
Captopril—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000654	0.00249	CcSEcCtD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000613	0.00439	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000608	0.00436	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000608	0.00436	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000555	0.00398	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000542	0.00389	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—SPP1—nephrolithiasis	0.00052	0.00373	CbGpPWpGaD
Captopril—CYP2D6—renal system—nephrolithiasis	0.000514	0.00179	CbGeAlD
Captopril—ALB—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000507	0.00364	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000507	0.00364	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000506	0.00363	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000506	0.00363	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000501	0.00359	CbGpPWpGaD
Captopril—CYP2D6—kidney—nephrolithiasis	0.000497	0.00173	CbGeAlD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000496	0.00356	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000496	0.00356	CbGpPWpGaD
Captopril—F2—Hemostasis—SLC7A9—nephrolithiasis	0.000471	0.00338	CbGpPWpGaD
Captopril—F2—Hemostasis—DGKH—nephrolithiasis	0.000471	0.00338	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000471	0.00337	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000471	0.00337	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000441	0.00316	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00042	0.00301	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00042	0.00301	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000411	0.00294	CbGpPWpGaD
Captopril—ABCB1—nephron tubule—nephrolithiasis	0.000407	0.00142	CbGeAlD
Captopril—F2—Signaling by GPCR—RGS14—nephrolithiasis	0.000401	0.00287	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000385	0.00276	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000385	0.00276	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000381	0.00273	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000376	0.00269	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000376	0.00269	CbGpPWpGaD
Captopril—ABCB1—renal system—nephrolithiasis	0.00037	0.00129	CbGeAlD
Captopril—ALB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000363	0.0026	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ADCY10—nephrolithiasis	0.00036	0.00258	CbGpPWpGaD
Captopril—ABCB1—kidney—nephrolithiasis	0.000358	0.00125	CbGeAlD
Captopril—ALB—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000357	0.00256	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000357	0.00256	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000349	0.00251	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000349	0.00251	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—PTH—nephrolithiasis	0.000349	0.0025	CbGpPWpGaD
Captopril—ABCB1—cortex of kidney—nephrolithiasis	0.000348	0.00121	CbGeAlD
Captopril—MMP9—Extracellular matrix organization—SPP1—nephrolithiasis	0.000341	0.00244	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000335	0.0024	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000319	0.00228	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000316	0.00227	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000316	0.00227	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000311	0.00223	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000311	0.00223	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RGS14—nephrolithiasis	0.000306	0.0022	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000298	0.00214	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000282	0.00202	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ADCY10—nephrolithiasis	0.000278	0.00199	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000277	0.00199	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000277	0.00199	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—DGKH—nephrolithiasis	0.000271	0.00194	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000258	0.00185	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000258	0.00185	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000249	0.00178	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000247	0.00177	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RGS14—nephrolithiasis	0.000237	0.0017	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000226	0.00162	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000226	0.00162	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000215	0.00154	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—DGKH—nephrolithiasis	0.000207	0.00148	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000207	0.00148	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—PTH—nephrolithiasis	0.000197	0.00141	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000196	0.0014	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000195	0.0014	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000195	0.0014	CbGpPWpGaD
Captopril—ALB—Hemostasis—DGKH—nephrolithiasis	0.000187	0.00134	CbGpPWpGaD
Captopril—ALB—Hemostasis—SLC7A9—nephrolithiasis	0.000187	0.00134	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000182	0.0013	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000182	0.0013	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PTH—nephrolithiasis	0.000179	0.00128	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000171	0.00123	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000171	0.00123	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000162	0.00116	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000162	0.00116	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00016	0.00115	CbGpPWpGaD
Captopril—F2—Signaling Pathways—DGKH—nephrolithiasis	0.00016	0.00115	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000159	0.00114	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000159	0.00114	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CHRM3—nephrolithiasis	0.00015	0.00107	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000142	0.00102	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000142	0.00102	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PTH—nephrolithiasis	0.000137	0.000981	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000129	0.000928	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CHRM3—nephrolithiasis	0.000116	0.000828	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000113	0.000813	CbGpPWpGaD
Captopril—ALB—Metabolism—GRHPR—nephrolithiasis	0.000112	0.000805	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PTH—nephrolithiasis	0.000106	0.000757	CbGpPWpGaD
Captopril—ALB—Metabolism—AGXT—nephrolithiasis	0.0001	0.000717	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GRHPR—nephrolithiasis	9.84e-05	0.000705	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GRHPR—nephrolithiasis	9.27e-05	0.000664	CbGpPWpGaD
Captopril—ABCB1—Metabolism—AGXT—nephrolithiasis	8.77e-05	0.000628	CbGpPWpGaD
Captopril—ALB—Metabolism—SLC26A1—nephrolithiasis	8.51e-05	0.00061	CbGpPWpGaD
Captopril—ALB—Metabolism—APRT—nephrolithiasis	8.51e-05	0.00061	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—AGXT—nephrolithiasis	8.26e-05	0.000592	CbGpPWpGaD
Captopril—ABCB1—Metabolism—APRT—nephrolithiasis	7.46e-05	0.000534	CbGpPWpGaD
Captopril—ABCB1—Metabolism—SLC26A1—nephrolithiasis	7.46e-05	0.000534	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—APRT—nephrolithiasis	7.03e-05	0.000504	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	7.03e-05	0.000504	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SPP1—nephrolithiasis	6.87e-05	0.000493	CbGpPWpGaD
Captopril—ALB—Metabolism—AQP1—nephrolithiasis	6.06e-05	0.000435	CbGpPWpGaD
Captopril—ALB—Metabolism—CHRM3—nephrolithiasis	5.48e-05	0.000393	CbGpPWpGaD
Captopril—ABCB1—Metabolism—AQP1—nephrolithiasis	5.31e-05	0.000381	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SPP1—nephrolithiasis	5.31e-05	0.00038	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—AQP1—nephrolithiasis	5.01e-05	0.000359	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CHRM3—nephrolithiasis	4.8e-05	0.000344	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CHRM3—nephrolithiasis	4.53e-05	0.000324	CbGpPWpGaD
